Targeting Clonal Mutations in Solid Tumors with Personalized Oncolytic Microbes

Immunotherapy has shown much promise for blood cancers, which may all be treatable or curable soon, especially if hematopoietic stem cells (HSCs) are harvested and frozen ahead of time for each individual. Alternatively, if sufficient numbers of HSCs can be produced from induced pluripotent stem cells derived from solid cell types, freezing cells ahead of time would not be necessary. Unfortunately, solid tumors are still extremely difficult to treat. Immunotherapy has helped in some instances for solid tumors, e.g., melanoma - and immunotherapy may eventually be able to cure all solid tumors for reasons that are somewhat unclear currently. However, there may be a more direct way to treat solid tumors. I have written multiple articles about targeting truncal, i.e., clonal, mutations in solid tumors as a means of eliminating them. This would be a treatment specific to each patient. There are thousands of clonal point mutations on average in a solid tumor patient’s cancer. This may essentially ensure that all of a solid tumor patient’s cancer cells could be targeted and eliminated.